Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 7.78 INR
Change Today 0.00 / 0.00%
Volume 0.0
ARL On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

auro laboratories ltd (ARL) Snapshot

Open
7.78
Previous Close
7.41
Day High
7.78
Day Low
7.78
52 Week High
09/30/14 - 10.20
52 Week Low
07/16/14 - 5.23
Market Cap
48.5M
Average Volume 10 Days
724.6
EPS TTM
0.33
Shares Outstanding
6.2M
EX-Date
--
P/E TM
23.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for AURO LABORATORIES LTD (ARL)

Related News

No related news articles were found.

auro laboratories ltd (ARL) Related Businessweek News

No Related Businessweek News Found

auro laboratories ltd (ARL) Details

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations. It offers APIs for various drugs comprising antihistamine, muscle relaxant, diuretic, iron deficiency, anti diabetic, anti fungal, anti ulcer, iodine supplement, anti malaria, analgesics, antacids, and anti inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company’s intermediates product line comprises glibenclamde sulphonamide for use in the API glibenclamide; cis-bramo benzoate and cls-tosylate, which is used in the API ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in the API sildenafil citrate; and 5-bromo phthalide that is used in the API citalopram. In addition, it undertakes custom manufacturing projects for agrochemicals, intermediates, and APIs, as well as provides specialty chemicals products. The company also exports its products to Southeast Asia, the Middle East, and European countries. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.

60 Employees
Last Reported Date: 08/7/14
Founded in 1989

auro laboratories ltd (ARL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

auro laboratories ltd (ARL) Key Developments

Auro Laboratories Ltd. Appoints Kavita Vijayakant Sharma as Woman Director

Auro Laboratories Ltd. announced that the Board of Directors of the company at its meeting held on March 27, 2014 have appointed Ms. Kavita Vijayakant Sharma as a Woman Director of the company with immediate effect. This appointment is in compliance with the Listing Agreement with BSE Ltd. and Section 149 of the Companies Act, 2013 read with Rule 3 of the Companies (Appointment of Directors) Rules 2014.

Auro Laboratories Ltd., Board Meeting, Mar 27, 2015

Auro Laboratories Ltd., Board Meeting, Mar 27, 2015. Agenda: To appoint Ms. Kavita Vijayakant Sharma as a Woman Director of the company with immediate effect.

Auro Laboratories Ltd. Reports Unaudited Stand-Alone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Auro Laboratories Ltd. reported unaudited stand-alone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales/income from operations was INR 83.258 million against INR 81.171 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 5.268 million against INR 5.021 million a year ago. Profit from ordinary activities before tax was INR 0.931 million compared to INR 0.886 million for the same period a year ago. Net profit was INR 0.931 million or INR 0.15 basic and diluted earnings per share against INR 0.886 million or INR 0.14 basic and diluted earnings per share a year ago. For the nine months, the company reported net sales/income from operations was INR 241.419 million against INR 277.419 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 13.996 million against INR 16.429 million a year ago. Profit from ordinary activities before tax was INR 0.931 million compared to INR 0.886 million for the same period a year ago. Net profit was INR 2.688 million or INR 0.43 basic and diluted earnings per share against INR 3.702 million or INR 0.59 basic and diluted earnings per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARL:IN 7.78 INR 0.00

ARL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARL.
View Industry Companies
 

Industry Analysis

ARL

Industry Average

Valuation ARL Industry Range
Price/Earnings 10.2x
Price/Sales 0.2x
Price/Book 0.7x
Price/Cash Flow 4.0x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AURO LABORATORIES LTD, please visit www.aurolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.